NOBILI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.211
EU - Europa 5.464
AS - Asia 998
AF - Africa 7
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 12.685
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.182
PL - Polonia 2.737
IT - Italia 722
IE - Irlanda 671
SE - Svezia 465
HK - Hong Kong 362
RU - Federazione Russa 284
CN - Cina 242
DE - Germania 164
SG - Singapore 133
JO - Giordania 116
FI - Finlandia 102
GB - Regno Unito 98
UA - Ucraina 76
TR - Turchia 50
VN - Vietnam 48
CH - Svizzera 35
AT - Austria 24
BE - Belgio 24
FR - Francia 21
CA - Canada 20
KR - Corea 19
ES - Italia 17
IN - India 17
NL - Olanda 13
MX - Messico 7
IR - Iran 5
SC - Seychelles 4
DK - Danimarca 3
AL - Albania 2
BT - Bhutan 2
GR - Grecia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
TN - Tunisia 2
AU - Australia 1
BR - Brasile 1
CZ - Repubblica Ceca 1
EU - Europa 1
ID - Indonesia 1
JP - Giappone 1
MK - Macedonia 1
MU - Mauritius 1
NP - Nepal 1
PT - Portogallo 1
RO - Romania 1
TW - Taiwan 1
Totale 12.685
Salva come PNG Salva come JPEG
Città #
Warsaw 2.728
Fairfield 884
Chandler 669
Dublin 669
Ashburn 479
Woodbridge 433
Cambridge 385
Seattle 377
Houston 366
Wilmington 317
Ann Arbor 224
Hong Kong 206
Altamura 179
Princeton 173
Lawrence 168
Florence 130
Jacksonville 126
Boston 120
Beijing 104
Boardman 86
Buffalo 82
Singapore 74
Medford 68
Moscow 67
Shanghai 67
Bremen 63
San Diego 60
Falls Church 47
Kent 42
Izmir 36
Bern 34
Dong Ket 32
New York 32
Norwalk 31
Dearborn 30
Vienna 24
Hillsboro 22
Brussels 21
Phoenix 21
Rome 20
London 17
Toronto 17
West Jordan 16
Barcelona 15
Los Angeles 15
Andover 12
Palermo 12
Pune 11
Redmond 11
Catania 10
Bari 8
Guadalajara 8
Milan 8
Seongnam 8
Auburn Hills 7
Guangzhou 7
Laurel 7
Tappahannock 7
Council Bluffs 6
Seoul 6
Turin 6
Washington 6
Bologna 5
Fiesole 5
Frankfurt Am Main 5
Kilburn 5
Kunming 5
Modena 5
Biella 4
Cagliari 4
Lastra a Signa 4
Perugia 4
Redwood City 4
Renton 4
Romainville 4
Trumbull 4
Castelliri 3
Coreno Ausonio 3
Genoa 3
Lanciano 3
Latina 3
Leawood 3
Naaldwijk 3
Padova 3
Pavia 3
Philadelphia 3
Poggibonsi 3
Prato 3
Reggio Emilia 3
San Mateo 3
Serra 3
Sesto Fiorentino 3
Shenzhen 3
Sinalunga 3
Taranto 3
Tehran 3
Udine 3
Verona 3
Vibo Valentia 3
Alghero 2
Totale 10.049
Salva come PNG Salva come JPEG
Nome #
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 263
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 250
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 247
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 246
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 243
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 238
Emerging drugs in refractory colorectal cancer 232
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 227
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 226
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 222
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 221
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 221
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 213
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 208
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 204
Natural compounds for cancer treatment and prevention 203
Druggable Targets in Pancreatic Adenocarcinoma 199
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 199
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 193
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 172
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 167
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 163
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 157
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 155
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 132
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 119
Pharmacogenetics: Implementing personalized medicine 118
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 113
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 112
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 111
Cellular pharmacology of gemcitabine. 110
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 108
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 106
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 106
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 106
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 103
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 103
Chronic inflammation in urothelial bladder cancer 99
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 93
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 90
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 90
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 89
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 87
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 85
Pharmacological strategies for overcoming multidrug resistance. 84
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 82
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. 82
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 81
Prognostic factors in primary and iterative surgery of colorectal liver metastases 80
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 80
Postoperative chemotherapy in resected gastric cancer: results of a single center experience. 79
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 78
The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. 78
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 77
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 77
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 76
Genomic and genetic alterations influence the progression of gastric cancer 74
Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? 73
Size dependent biological profiles of PEGylated gold nanorods 73
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. 73
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 72
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 71
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 70
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer 69
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (pts) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT 67
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 67
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 67
Role of ATP-binding cassette transporters in cancer initiation and progression 66
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 65
Biweekly (BW) chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT11), infusional 5-fluorouracil/folinic acid (FU/FA) in patients (PTS) with metastatic colorectal cancer (MCRC) pretreated with CPT11- or OHP-based CHT. 65
HLA-G 3’UTR +2960 14-bp INDEL (Ins/Del) polymorphism is associated to improved DFS of stage II-III CRC patients. 65
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 64
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 64
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 62
Next-Generation Sequencing to Identify Rare Variants Related to FL-Toxicity 62
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 61
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 60
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 59
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 59
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 59
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 58
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 58
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 57
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 57
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 57
Farmaci Antineoplastici - Farmaci antiormonali 56
Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale 56
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 56
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 54
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 53
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 53
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 51
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. 47
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 46
OXALIPLATIN PLUS RALTITREXED IN THE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER: A PHASE II STUDY 46
Farmaci antineoplastici - Antimetaboliti 45
Chemioterapici Antimicrobici - Glicopeptidi 44
Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer: Preliminary results 42
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties 41
Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study 41
Totale 10.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.449 0 228 96 188 309 292 284 316 255 184 236 61
2020/20211.826 140 184 70 208 120 196 115 132 186 255 91 129
2021/20221.089 28 116 62 47 30 69 40 101 65 49 153 329
2022/20233.103 276 533 119 279 219 560 372 183 379 15 71 97
2023/20241.229 50 117 194 37 91 142 99 266 30 79 65 59
2024/2025415 312 103 0 0 0 0 0 0 0 0 0 0
Totale 12.944